Biotech Values

[DewDiligence]

I vaguely recall ABT had a drug moving under the radar into phase 2 for an undisclosed target, but now I can't find the trial listed

ABT claims to have a robust HCV pipeline, but it plays its cards very close to the vest and discloses as little as possible to investors. Here’s what ABT said about HCV on its 2Q09 CC*:

We have three hepatitis C compounds in human clinical trials including both polymerase and protease inhibitors. Abbott is the only company with these two classes of compounds in development with the potential to have the best HCV drug cocktail in the market in the coming years.

The latter half of the above is a misstatement, of course: Roche and IDIX have polymerase and protease inhibitors in development and GILD probably does too.

*http://seekingalpha.com/article/149067-abbott-laboratories-q2-2009-earnings-call-transcript?page=-1